Current opportunities:

The following compounds are currently open for out licensing and/or co-development with a strategic partner:

AIC499

Novel resistance-breaking gram-negative antibiotic

AIC284

Innovative treatment against autoimmunity

AIC649

Proprietary immune modulator and potential cure for chronic hepatitis B infection